Host John Russell, MD
Guest Philip Philip, MD, PhD, FACP
Guest Kurt Tauer, MD, FACP
Dr Philip and Dr. Tauer are paid consultants for Amgen
When your patients are diagnosed with metastatic colorectal cancer (mCRC), how does biomarker status impact treatment options? Join Dr. John Russell as he hosts a discussion with Dr. Philip Philip, medical oncologist and Professor at the Karmanos Cancer Institute, and Dr. Kurt Tauer, medical oncologist at the West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, on the importance of biomarker identification in mCRC and how it can help determine appropriate treatment options.
In this discussion, Drs. Philip and Tauer will review:
Interested in learning more about extended RAS testing and its role in the first-line treatment of mCRC? Visit Vectibix.com
Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC):
Limitation of Use
Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.